evitria AG’s Post

🚀 𝐏𝐫𝐨𝐦𝐢𝐬𝐢𝐧𝐠 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐟𝐨𝐫 𝐚 𝐛𝐢𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐢𝐧 𝐋𝐮𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭! 🚀 Summit Therapeutics, Inc. has recently shared encouraging Phase 3 trial data for their experimental drug, 𝐢𝐯𝐨𝐧𝐞𝐬𝐜𝐢𝐦𝐚𝐛, in the treatment of advanced non-small cell lung cancer (NSCLC). This innovative therapy, a 𝐛𝐢𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐲 targeting both PD-1 and VEGF pathways, has shown remarkable potential when compared to Merck’s Keytruda. 🎯 𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬: • 𝐏𝐫𝐨𝐠𝐫𝐞𝐬𝐬𝐢𝐨𝐧-𝐅𝐫𝐞𝐞 𝐒𝐮𝐫𝐯𝐢𝐯𝐚𝐥: Ivonescimab nearly doubled the time tumors remained stable (11+ months vs. 6 months for Keytruda). 📊 • 𝐁𝐢𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐌𝐞𝐜𝐡𝐚𝐧𝐢𝐬𝐦: By simultaneously targeting PD-1 and VEGF, ivonescimab may offer enhanced efficacy in halting tumor growth. 💡 • 𝐑𝐞𝐝𝐮𝐜𝐞𝐝 𝐑𝐢𝐬𝐤: A 49% reduction in cancer progression or death was observed in the trial. 🔄 However, while these results are highly promising, there are still 𝐜𝐫𝐢𝐭𝐢𝐜𝐚𝐥 𝐮𝐧𝐤𝐧𝐨𝐰𝐧𝐬: • ❓The study didn’t include the current standard combination of 𝐊𝐞𝐲𝐭𝐫𝐮𝐝𝐚 + 𝐜𝐡𝐞𝐦𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲, which raises questions about the drug’s comparative performance. • 🌍The trial was conducted in China, so the 𝐠𝐞𝐧𝐞𝐫𝐚𝐥𝐢𝐳𝐚𝐛𝐢𝐥𝐢𝐭𝐲 of the results needs further validation. 🔬 𝐅𝐮𝐫𝐭𝐡𝐞𝐫 𝐬𝐭𝐮𝐝𝐢𝐞𝐬 are underway to answer these questions, and the global medical community eagerly awaits more data, including overall survival rates. If successful, ivonescimab could reshape the treatment landscape for lung cancer patients worldwide. #InnovationInOncology #LungCancer #Ivonescimab #ClinicalTrials #CancerResearch #Pharma

#Claudin18.2 Claudin-18.2 is a protein involved in forming tight junctions between cells, particularly in the stomach. In cancer, it's overexpressed in gastric cancer cells, making it a potential target for therapy. Researchers are exploring antibody-based treatments to selectively target and treat cancer cells that overexpress this protein. Clinical trials are ongoing to evaluate its effectiveness in treating gastric cancer. #DIMA now offers a comprehensive range of products and services related to the Claudin18.2 target. The product includes active recombinant #proteins, Biosimilar #antibodies, and FC-validated monoclonal antibodies. Their services encompass various protein antibody customization services, antibody humanization, and affinity maturation services. To expedite the development of Claudin18.2 biotherapy, DIMA Biotech has established a Claudin18.2 target single B-cell seed library. This resource allows for the rapid acquisition of lead antibody molecules in as little as 28 days. Additionally, DIMA Biotech has undertaken CAR-T or ADC molecule construction and functional validation for some existing Claudin18.2 lead antibody molecules. For specific data inquiries and further information, feel free to contact us. Read more: https://lnkd.in/e-j5ZPX3

Fight Cancer with Precision Medicines: Antibody Drug Conjugate (ADC) delivery of a cytotoxic drug allows greater specificity than use of the drug alone. This therapeutic modality targets cancer cells while reducing the potential impact on normal cells to improve efficacy and safety. Eurofins Discovery’s OncoPanel® and BioMAP® platforms can aid new ADC therapeutic development! OncoPanel ✔ Supports lead optimization with routine screening using any of our 300+ human tumor cell lines. ✔ Enables the identification of sensitive and resistant tumor types, along with related predictive genomic biomarkers. BioMAP ✔ Generates an actionable phenotypic fingerprint using the Diversity PLUS panel of 12 biological models with 148 clinically relevant protein biomarker readouts. ✔ Enables the identification of broader biological effects and potential toxicity signatures to help de-risk programs by comparison with 4,500+ therapeutic and reference agent profiles. Our experts can help you accelerate & de-risk your ADC program. Contact us today. https://lnkd.in/gDh2fzBP #DrugDiscovery #ADC #EurofinsDiscovery

On #India’s 78th birthday, here’s highlighting some homegrown #cancer #immunotherapy Zumutor Biologics, a Bangalore + Boston startup, has developed a first-in-class anti-LLT-1 monoclonal antibody that they have codenamed #ZM008 The #ZM008 sequence was identified on Zumutor Biologics’ cool phage display human antibody library #ZM008’s #MechanismOfAction (infographic below) #ZM008, an anti-LLT-1 monoclonal Antibody, binds to Lectin-like transporter-1 (LLT-1, CLEC2D) on #cancer cells thereby preventing its interaction with CD161 CD161 is a #glycoprotein found on #NaturalKiller cells, and its interaction with LLT-1 found on human cells serves as an #ImmuneCheckpoint This interaction helps in identifying self cells but is highjacked by #cancer cells as well. #ZM008 is therefore expected to unlock the potency of #NaturalKiller cells that would now target #cancer cells #ZM008 blocks the interaction of LLT-1 on cancer cells and CD161 leading to enhanced #NaturalKiller cell-dependent cytotoxicity or #cancer cell killing The advantage of this mechanism of action is the potential to use in conjunction with T-cell based #immunotherapy or even in those that are refractory to the older-generation T-cell #ImmuneCheckpoint inhibitors #ZM008 Phase I trial in 33 individuals Dose escalation commenced in the US after receiving an IND from the FDA Will be first tried as a single agent but then also in conjugation with Pembrolizumab Inclusion criteria are set to allow multiple different solid tumors Primary outcome is dose limiting toxicity, secondary outcomes include pharmacodynamic measures such as progression free survival as well as pharmacokinetic measures such as concentration vs. time AUC and Cmax Excited to follow the clinical development of #ZM008! Link to trial design: https://lnkd.in/g7eMb6HJ

🚀 Discover the Future of Medicine with Our Latest Report on Antibody-Drug Conjugates (ADCs) 🌐 Discover how antibody-drug conjugates (ADCs) may be used to treat cancer in the future! Key players in oncology, these novel medicines combine the potent anti-cancer properties of cytotoxic medications with the selectivity of monoclonal antibodies. ADC sales are expected to soar from $10.8 billion in 2023 to $47.0 billion by 2029, putting the global market for these devices on a high-growth trajectory. This indicates a strong compound annual growth rate (CAGR) of 28.4% between 2024 and 2029. 🚀 What is the reason behind the quick growth? An expanding number of clinical settings are finding value in adjuvant chemotherapy (ADC) because of its focused strategy that minimizes adverse effects and improves treatment outcomes for cancer patients. Global cancer treatment landscapes are predicted to undergo significant changes due to the sustained innovation spurred by the breakthroughs in ADC technology. Don’t miss out on the latest insights! Our report dives deep into market trends, key players, and the potential impact of ADCs over the next five years. https://bit.ly/47AKhiv #AntibodyDrugConjugates #BiotechInnovation #CancerResearch #HealthcareTransformation #MarketTrends #Oncology

Nature Reviews Cancer article outlining the scientific, clinical and economic rationale for creating a platform to conduct ctDNA-guided clinical trials in the MED (molecular evidence of disease) setting after curative-intent therapy for early-stage cancer Co-authored by Eric Lander, Levi Garraway Nikhil Wagle et al. 1) Standing platform — an infrastructure to support ongoing identification and trial enrolment of patients with cancer with early MED after curative-intent therapy for early-stage cancer, based on the presence of circulating tumour DNA. 2) MED strongly predicts subsequent recurrence, with the vast majority of patients showing radiographic evidence of disease within 18 months. 3) Such a platform would allow efficient testing of many treatments, from small exploratory studies to larger pivotal trials. 4) Trials enrolling patients with MED but without radiographic evidence of disease have the potential to advance drug evaluation because they can be smaller (given high probability of recurrence) and faster (given short time to recurrence) than conventional adjuvant trials. 5) Circulating tumour DNA may also provide a valuable early biomarker of treatment effect, which would allow small signal-finding trials. https://lnkd.in/eYVaE4PU #medicine #research #healthcare #health #drugdevelopment #pharmaceutical #oncology #cancer #cancerresearch #innovation #technology

Great article highlighting the use of ctDNA as an early marker for disease recurrence. Thanks for sharing!

🚀 The CD3xCD20 #bispecific #antibody (#BsAb) market is heating up 🚀 Non-Hodgkin’s #lymphoma (NHL), the most common #blood #cancer globally, saw 544,000 new cases in 2020 alone (#WHO, GLOBOCAN). The two key B-cell NHL subtypes—follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)—affect over 280,000 people worldwide. While #monoclonal antibodies (#mAbs) have transformed NHL #treatment, relapsed or refractory cases post-mAb therapy have pushed the industry to seek more durable solutions. #CART therapies have made strides, but #manufacturing complexities and #toxicities have opened the door for bispecific antibodies, particularly T cell-engaging BsAbs, as off-the-shelf alternatives. Looking ahead, analysts project #Epcoritamab to lead the market with $2.75B in annual sales, followed by Roche’s BsAb assets at a combined $2B. Regeneron’s #Odronextamab, while promising, faces challenges from regulatory delays and a later market entry. The next frontier? Expanding into new NHL subtypes and earlier treatment lines. Regeneron is exploring Odronextamab in frontline follicular lymphoma (OLYMPIA-2), while Genmab is advancing Epcoritamab in combination with R-CHOP for DLBCL (EPCORE DLBCL-2). With 38 competitors in this space, the BsAb race is just heating up! 🏁 Below is a summary of active CD3xCD20 BsAbs in the clinic & the team put together a report on the #approved #drugs: https://lnkd.in/e-gSqrCN #Biotech #Oncology #NHL #BispecificAntibodies #Pharma #Innovation

Antibody Drug Conjugate Antibody-drug conjugates (ADCs) are a class of targeted cancer therapies designed to deliver potent cytotoxic agents directly to cancer cells, sparing healthy tissues and minimizing side effects. ADCs consist of three key components: 1. Monoclonal Antibody (mAb): This antibody specifically binds to a unique antigen present on the surface of cancer cells. It acts as a targeting vehicle that guides the drug to the tumor. 2. Cytotoxic Drug (Payload): The drug, often a highly potent chemotherapy agent, is attached to the antibody and is capable of killing the cancer cell once delivered. These drugs are too toxic to be administered systemically on their own. 3. Linker: The chemical bond attaches the cytotoxic drug to the antibody. The stability of the linker is crucial; it must remain intact in the bloodstream to avoid premature release of the drug, but it should release the drug once the ADC reaches the tumor site. https://lnkd.in/gGX9V4Bd #AntibodyDrugConjugates #ADCs #TargetedTherapy #CancerTreatment #MonoclonalAntibodies #Alphalifetech

Antibody Drug Conjugate Antibody-drug conjugates (ADCs) are a class of targeted cancer therapies designed to deliver potent cytotoxic agents directly to cancer cells, sparing healthy tissues and minimizing side effects. ADCs consist of three key components: 1. Monoclonal Antibody (mAb): This antibody specifically binds to a unique antigen present on the surface of cancer cells. It acts as a targeting vehicle that guides the drug to the tumor. 2. Cytotoxic Drug (Payload): The drug, often a highly potent chemotherapy agent, is attached to the antibody and is capable of killing the cancer cell once delivered. These drugs are too toxic to be administered systemically on their own. 3. Linker: The chemical bond attaches the cytotoxic drug to the antibody. The stability of the linker is crucial; it must remain intact in the bloodstream to avoid premature release of the drug, but it should release the drug once the ADC reaches the tumor site. https://lnkd.in/gjbhXwxQ #AntibodyDrugConjugates #ADCs #TargetedTherapy #CancerTreatment #MonoclonalAntibodies #Alphalifetech